Technology ID
TAB-1185

Transmission-Blocking Vaccine Against Malaria (1)

E-Numbers
E-035-1991-0
Co-Inventors
Kaslow, David
Applications
Vaccines­­­
Therapeutic Areas
Infectious Disease
Lead IC
NIAID
A transmission blocking vaccine developed against malaria contains a recombinant virus, which encodes a unique portion of the sexual stage surface antigen of Plasmodium falciparum (referred to as Pfs25), or the Pfs25 protein purified from infected host cells. Mice inoculated with the recombinant virus developed antibodies capable of blocking transmission of the virus. None of the monoclonal antibodies known to block transmission recognize the reduced Pfs25 antigen. This vaccine, which induces high, long-lasting titers at low cost, can be useful for controlling malaria.
Licensing Contact:
Hurley, Benjamin
benjamin.hurley@nih.gov
Phone: +1 240 276 5489